- Home
- OP vs NLSP Comparison
OP vs NLSP Comparison
Compare OP & NLSP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- NLSP
- Stock Information
- Founded
- OP 2021
- NLSP 2015
- Country
- OP Greece
- NLSP Switzerland
- Employees
- OP N/A
- NLSP N/A
- Industry
- OP
- NLSP Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- NLSP Health Care
- Exchange
- OP Nasdaq
- NLSP Nasdaq
- Market Cap
- OP 14.3M
- NLSP 12.4M
- IPO Year
- OP N/A
- NLSP 2021
- Fundamental
- Price
- OP $1.24
- NLSP $2.15
- Analyst Decision
- OP
- NLSP
- Analyst Count
- OP 0
- NLSP 0
- Target Price
- OP N/A
- NLSP N/A
- AVG Volume (30 Days)
- OP 1.2M
- NLSP 186.7K
- Earning Date
- OP 12-02-2025
- NLSP 10-17-2025
- Dividend Yield
- OP N/A
- NLSP N/A
- EPS Growth
- OP N/A
- NLSP N/A
- EPS
- OP N/A
- NLSP N/A
- Revenue
- OP $19,435,000.00
- NLSP N/A
- Revenue This Year
- OP N/A
- NLSP N/A
- Revenue Next Year
- OP N/A
- NLSP N/A
- P/E Ratio
- OP N/A
- NLSP N/A
- Revenue Growth
- OP N/A
- NLSP N/A
- 52 Week Low
- OP $1.07
- NLSP $1.30
- 52 Week High
- OP $79.25
- NLSP $6.97
- Technical
- Relative Strength Index (RSI)
- OP 32.18
- NLSP 48.82
- Support Level
- OP $1.07
- NLSP $1.88
- Resistance Level
- OP $1.21
- NLSP $2.02
- Average True Range (ATR)
- OP 0.12
- NLSP 0.14
- MACD
- OP 0.76
- NLSP -0.02
- Stochastic Oscillator
- OP 25.37
- NLSP 33.33
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About NLSP NLS Pharmaceutics Ltd.
NLS Pharmaceutics Ltd a clinical-stage biopharmaceutical company focused on the discovery and development of inventive therapies for patients with rare and complex CNS disorders with unmet medical needs. Its compound, mazindol, a triple monoamine reuptake inhibitor and partial orexin receptor 2 agonist, in a proprietary ER formulation, is being developed for the treatment of narcolepsy, IH (follow-on indication), and potentially ADHD (back-up indication). Its lead products are Quilience, to treat narcolepsy and Nolazol, to treat ADHD.